Core Insights - BioHarvest Sciences Inc. has launched a new product in its Vinia line, a daily "2X formula" chew designed for athletes and active consumers, delivering 12mg of Piceid Resveratrol, which is double the amount found in the original capsule format [1][5]. Product Development - The new chew was developed based on insights gained from working with athletes during the NFL combine, indicating that a higher dosage was necessary for noticeable effects [5]. - The chew is designed to be convenient, great tasting, and low in calories, containing only 15 calories per chew [6]. Market Positioning - The product is certified by Informed Sport, which is crucial for athletes concerned about anti-doping standards, thus expanding its market appeal to both amateur and professional athletes [6][7]. - This certification opens new distribution channels and is expected to drive incremental revenue and customer acquisition for the Vinia brand [8]. Future Strategy - The company plans to continue expanding its product line with a "Vinia inside" strategy, focusing on superior science and efficacy, and has plans to launch a new product targeting the US$16 billion US hydration market within the next 120 days [9][10].

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive has bureaus and studios in key finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2][3] Group 2 - The company is focused on sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] - Proactive adopts technology to enhance workflows and improve content production [4] - Automation and software tools, including generative AI, are used, but all content is edited and authored by humans [5]

Informed Sport is the world's leading testing and certification program for brands producing sports and nutritional supplements. Designed for elite sport, it protects athletes from inadvertent doping caused by supplements contaminated with banned substances. As such, it is recognised by sporting and governing bodies, anti-doping bodies and nutrition industry organisations, and the armed and special forces. https://sport.wetestyoutrust.com/ BioHarvest Launches Informed Sport-Certified VINIA DailyChews 2X For ...

Core Viewpoint - The article emphasizes the importance of confirming the sustainability of stock trends for successful short-term investing, highlighting that price movements should be supported by strong fundamentals and positive earnings estimates [1][2]. Group 1: Stock Performance - BioHarvest Sciences Inc. (BHST) has shown a solid price increase of 26.6% over the past 12 weeks, indicating investor confidence in its potential upside [4]. - The stock has also increased by 6% over the past four weeks, suggesting that the upward trend is still intact [5]. - BHST is currently trading at 93.6% of its 52-week high-low range, indicating a potential breakout [5]. Group 2: Fundamental Strength - BHST holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [6]. - The stock has an Average Broker Recommendation of 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term price performance [7]. Group 3: Investment Strategy - The article suggests using the "Recent Price Strength" screen to identify stocks like BHST that are on an uptrend supported by strong fundamentals [3]. - It also mentions that there are over 45 Zacks Premium Screens available for investors to find stocks that fit their personal investing styles [8].

Core Insights - BioHarvest Sciences Inc. has announced a new contract targeting the plant-based fragrance compound market, utilizing its proprietary botanical synthesis platform [1] - The contract focuses on a rare plant that is under threat from overharvesting and habitat loss, aligning with the company's commitment to sustainability [4] - The market for natural, plant-derived fragrance ingredients is experiencing growth due to increasing consumer awareness [1][3] Company Developments - The CEO of BioHarvest Sciences, Ilan Sobel, emphasized the significance of the new contract in the multi-billion dollar fragrance industry, particularly in the segment focused on natural plant-derived compounds [3] - The company has developed significant AI capabilities to identify the specific plant species for the fragrance compound, enhancing its discovery process [5] - The project will be executed in two stages, with strict NDAs in place for the first stage, which involves sourcing the plant and conducting tissue culture work [6] Revenue Potential - Stage two of the project will involve scaling up cell growth in bioreactors, aiming for cost efficiency and significant royalty margins [7] - The company aims to demonstrate the breadth of its botanical synthesis platform, which can produce various plant-based compounds, thereby impacting major billion-dollar industries [8]

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced news journalists who produce independent content across various financial markets [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content includes insights into sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is committed to adopting technology to enhance its content creation and workflow processes [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all published content is edited and authored by humans [5]

Core Insights - BioHarvest Sciences Inc. has secured a new contract for developing a plant-based fragrance compound, targeting the multi-billion-dollar fragrance and scents market [1][3] - The contract will utilize the company's proprietary Botanical Synthesis technology and advanced AI-assisted research capabilities to identify specific plant species for efficient production [2][4] - The agreement includes milestone-based payments and a non-disclosure agreement for the initial stage of the project [3] Company Overview - BioHarvest is a leader in Botanical Synthesis, leveraging patented technology to grow plant-based compounds without the need for the actual plants [5] - The company operates in two major business verticals: as a contract development and manufacturing organization (CDMO) and as a creator of proprietary nutraceutical health and wellness products [5][6] - The CEO emphasized the contract's potential to expand the company's reach into the high-value fragrance space while contributing to the conservation of threatened plant species [4]

Core Insights - BioHarvest Sciences Inc. has transitioned to stage two of its partnership with a pharmaceutical company, marking a significant milestone in the development of plant-derived biological materials for approved drugs [1][4] - The transition involves cultivating specific plant cells in liquid media within small-scale bioreactors, which is a crucial step towards commercial scalability [2][5] Group 1 - Stage one focused on identifying and working with specific plant cells to produce targeted phyto-medicinal compounds using solid media in petri dishes [4][5] - Stage two represents a shift to liquid media cultivation in small-scale bioreactors, which is essential for scaling up production [5][6] - Successful completion of stage two will lead to stage three, where cells will be grown in large-scale industrial bioreactors, with current operations already utilizing bioreactors of 1,200 liters and above [6] Group 2 - The company's mission is to discover, develop, manufacture, and democratize life-changing plant compounds that promote health and wellness while preserving the planet [7] - The transition from stage one to stage two validates the company's work and demonstrates the effectiveness of its botanical synthesis platform, which has been developed over 17 years [8]

Financial Performance - BioHarvest Sciences Inc. reported a quarterly loss of $0.13 per share, better than the Zacks Consensus Estimate of a loss of $0.15, and an improvement from a loss of $0.35 per share a year ago, indicating an earnings surprise of 13.33% [1] - The company posted revenues of $7.86 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.42%, and showing an increase from $5.34 million in the same quarter last year [2] Stock Performance - BioHarvest Sciences Inc. shares have increased approximately 6.8% since the beginning of the year, outperforming the S&P 500, which gained 0.2% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.10 on revenues of $8.77 million, and for the current fiscal year, it is -$0.30 on revenues of $40.4 million [7] - The estimate revisions trend for BioHarvest Sciences Inc. is mixed, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which BioHarvest Sciences Inc. belongs, is currently ranked in the top 28% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% of industries [8]

Financial Data and Key Metrics Changes - Revenue for Q1 2025 increased by 47% year-over-year to $7,900,000, exceeding guidance of $7,800,000, driven by balanced growth in the Vinia business [5][20] - Gross profit rose by 53% to $4,600,000, representing 58.5% of total revenue, up from 56.2% a year ago, primarily due to increased manufacturing scale and improved yield [20][21] - Net loss for Q1 2025 was $2,300,000, or $0.13 per share, compared to a net loss of $6,600,000, or $0.48 per share in the same quarter last year [21][22] Business Line Data and Key Metrics Changes - The Direct to Consumer Health and Wellness Products Division, led by Vinia, accounted for the majority of revenue, with total active subscribers exceeding 50,000 in the USA, and recurring subscribers making up 90% of revenue [6][13] - The Amazon channel represented 20% of the business, with improvements in customer conversion and repeat purchase rates [6] - The company launched new products, including a superfood tea lineup and plans for a hydration beverage, targeting significant market segments [9][12][60] Market Data and Key Metrics Changes - The company is expanding its reach into new consumer segments and channels, including international shipping and social media platforms like TikTok [42][43] - The market for non-GMO, plant-based compounds is growing, with increasing consumer awareness of health benefits related to blood flow and longevity [8][79] Company Strategy and Development Direction - The company aims to achieve adjusted EBITDA breakeven at $11,000,000 to $12,000,000 in quarterly revenue by the second half of 2025, focusing on balancing growth with profitability [17][18] - Strategic investments will be made in expanding the direct-to-consumer portfolio, enhancing R&D processes, and building AI-powered tools for CDMO services [18] - The company is targeting a 20% adjusted EBITDA margin for its direct-to-consumer division and higher margins in the CDMO segment [18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to execute its growth strategy and deliver life-changing compounds, highlighting the synergy between the direct-to-consumer and CDMO divisions [23][70] - The company is optimistic about the increasing interest from pharmaceutical companies in its botanical synthesis technology, which offers consistent and economically viable compounds [70][71] Other Important Information - The company raised $3,900,000 in debt financing during the quarter, increasing cash and cash equivalents to $3,400,000 [22] - The company is preparing to launch the olivoboscoside cell product in 2026, targeting significant market opportunities in liver health and cholesterol management [13][79] Q&A Session Summary Question: Can you provide details on the Phase two portion of the CDMO contract? - Management explained that Phase two involves moving from solid media to liquid media for cell conditioning, with an expected timeline of six to nine months [27][28] Question: How long will it take to narrow down targets with Tate and Lyle? - Management indicated that significant work is underway, with a comprehensive update expected by the end of the year [30] Question: Should we expect continued gross margin expansion as revenue grows? - Management affirmed the intention to drive continued gross profit margin improvement alongside revenue growth [31][32] Question: How many products contributed to revenue in Q1, and how many are expected by year-end? - Management noted that three product lines contributed to Q1 revenue, with expectations to increase to four by Q2 and five by Q3 or Q4 [36][38] Question: Will marketing costs drop due to increased ad inventory? - Management highlighted efforts to reduce marketing costs as a percentage of revenue while exploring new channels for customer acquisition [39][44] Question: Does the second quarter guidance include contributions from the CDMO business? - Management confirmed that the guidance includes revenue recognition from existing CDMO projects and potential new catalysts [45][46] Question: How many CDMO programs can be run concurrently? - Management stated that the current capacity allows for five to seven concurrent projects in stage one [49] Question: What is the long-term opportunity for the beauty product? - Management discussed a focused strategy on high-margin categories, including health and beauty, with plans for a launch in Q1 next year [60][61]